Catch up on the today's top five analyst initiations with this list compiled by The Fly: 1. Cigna (CI) initiated with a Buy at Stifel by analyst Thomas Carroll, who has a $169 price target on the stock. The analyst said CEO David Cordani has made significant strides in positioning Cigna for a post-Affordable Care Act world and expects the company to continue adding strategic components that improve its competitive position, either as a stand-alone organization or as a component of Anthem (ANTM). 2. Ultragenyx (RARE) initiated with a Buy at BofA/Merrill with a $72 price target. The firm said Ultragenyx is positioning itself for long-term growth and has 4 late-stage clinical assets to treat orphan diseases that could generate $1.2B in revenue. 3. Brown & Brown (BRO) initiated with an Underweight at JPMorgan by analyst Sarah DeWitt, who put a $32 price target on the stock. With most of the company's brokerage revenue commission-based, it is highly sensitive to softening Property & Casualty pricing, DeWitt said. 4. NeuroMetrix (NURO) initiated with a Buy at Rodman & Renshaw by analyst Raghuram Selvaraju, who has a $4.50 price target on the stock. The company's Quell platform is differentiated from competitors in that it is a drug-free, non-invasive and wearable neuro-stimulation device that can provide systemic and effective pain relief, Selvaraju said. 5. Acadia Realty Trust (AKR) initiated with an Outperform at Boenning & Scattergood by analyst Floris van Dijkum with an Outperform and $38 price target saying the Street does not appreciate the strong rent reversionary potential of its street retail portfolio that warrants a much lower cap rate of 3.35%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
click here.